Groupe de Recherche Action en Sante
12
0
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
88.9%
+2.4% vs industry average
8%
1 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
Role: collaborator
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
Role: collaborator
Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso
Role: collaborator
Evaluation of Electronic Pregnancy Registers and Mobile Applications for Monitoring Pregnancy Outcomes ( EVAPREAP )
Role: collaborator
Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC)
Role: collaborator
Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso
Role: collaborator
Malaria Burden in Pregnant Women and the Incidence of Pregnancy in a Cohort of Nulligravida
Role: lead
Follow-up of Immunological Pattern and Pregnancy Outcomes in Women Previously Received Placental Malaria Vaccine
Role: lead
Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso
Role: collaborator
Baseline Cohort Malaria Morbidity Study
Role: lead
A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
Role: collaborator
Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies
Role: lead
All 12 trials loaded